PITTSBURGH, April 22 /PRNewswire/ — Flexuspine, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted conditional approval to begin the initial phase of the Investigational Device Exemption (IDE) for a feasibility study of its FSU device. This is the first approved clinical study for a Total Spine Arthroplasty system in the […]

Share on LinkedInShare on FacebookShare on Google+Pin on PinterestEmail this to someone